A Study to Assess Safety of ABBV-916 & How Intravenous ABBV-916 Moves

Status Recruiting

Clinical Trial Summary

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating early AD. Adverse events, change in disease activity, and how ABBV-916 moves through body of participants will be assessed. ABBV-916 is an investigational drug being developed for the treatment of early AD. This study is conducted in 2 stages. Stage A is a multiple ascending dose study. There is a 1 in 4 chance that participants are assigned to receive placebo. Stage B is a proof-of-concept study. In Stage B, there is a 1 in 5 chance that participants will be assigned to receive placebo. The first 6 months of this study are "double-blind," which means that neither the trial participant nor the study doctors know which treatments will be given. This will be followed by a 2-year extension period in which all participants will receive ABBV-916. Approximately 195 participants aged 50-90 years will be enrolled in about 90 sites across the world. Participants will receive intravenous (IV) doses of ABBV-916 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for an additional 16 weeks. Participants will have the option of participating in a 2-year, open-label, Extension Period receiving IV ABBV-916. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, magnetic resonance imaging (MRI), blood tests, checking for side effects and completing questionnaires.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05291234
Study type	Interventional
Source	AbbVie
Contact	ABBVIE CALL CENTER
Phone	844-663-3742
Email	abbvieclinicaltrials@abbvie.com
Status	Recruiting
Phase	Phase 2
Start date	August 15, 2022
Completion date	March 26, 2031

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02503501` - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease	Phase 2
Recruiting	`NCT02854033` - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed	`NCT02593318` - Trial of Oxaloacetate in Alzheimer's Disease (TOAD)	Phase 1
Completed	`NCT02681172` - Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD	Phase 4
Completed	`NCT02264899` - MEMENTO-VAScular COmponents of Dementia	N/A
Completed	`NCT02531360` - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies	Phase 0
Recruiting	`NCT04570761` - Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study	N/A
Not yet recruiting	`NCT05592678` - δ in Dementia Clinical Trials	Phase 2/Phase 3
Not yet recruiting	`NCT05558709` - Social-cognitive Functioning: Validation of a New Neuropsychological Test	N/A
Recruiting	`NCT05059158` - Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Recruiting	`NCT02832921` - Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk	N/A
Completed	`NCT02370524` - Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease	Phase 1
Completed	`NCT01780519` - The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms	Phase 1
Completed	`NCT02103894` - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects	Phase 1
Completed	`NCT03802162` - A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355	Phase 1
Completed	`NCT01231971` - Alzheimer's Disease Neuroimaging Initiative 2
Active, not recruiting	`NCT05771428` - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease	Phase 2
Recruiting	`NCT06114745` - A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms